NCT04732754

Brief Summary

This study evaluates the cocoa supplementation and aerobic exercise on central pressure and arterial stiffness parameters in physically inactive middle-aged individuals. 500mg capsules will be offered to all patients. Of these, half will offer the content of 500mg of cocoa per capsule or placebo capsules. The placebo will contain a pharmacologically inert substance (microcrystalline cellulose) of the same color. A half will start 50' aerobic training 3 times/week while the other half will continue without exercise.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 27, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 1, 2021

Completed
7 months until next milestone

Study Start

First participant enrolled

September 1, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2022

Completed
Last Updated

August 20, 2021

Status Verified

August 1, 2021

Enrollment Period

1 year

First QC Date

January 27, 2021

Last Update Submit

August 19, 2021

Conditions

Keywords

FlavonoidsCocoaArterial StiffnessPhysical ExerciseCentral blood pressure

Outcome Measures

Primary Outcomes (1)

  • Arterial Stiffness by Pulse Wave Velocity

    The assessment of arterial stiffness will be carried out using the non-invasive method of PWV , which is obtained by dividing the carotid-femoral distance by the systolic wave travel time (in the unit of m / s) It will be checked by the Complior Analyzer equipment, with the volunteer in a supine position in an air-conditioned environment and controlled lighting in a LIC room, with the sensors placed over the right carotid and femoral arteries. The distance between the two points is measured by an infantometer and the data of pressure, total body weight and distance between the points of the sensors in the carotid artery and in the femoral artery are entered in the software to calculate the PWV. This analysis will be carried out before and after the intervention period.

    8 weeks

Study Arms (4)

Control Group (CG)

PLACEBO COMPARATOR

This group will receive placebo capsules to be consumed for 8 weeks daily and will not exercise;

Dietary Supplement: Control Group (CG)

Aerobic Exercise (AE)

ACTIVE COMPARATOR

This group will receive placebo capsules and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.

Dietary Supplement: Aerobic Exercise (AE)

Aerobic exercise + Theobroma cocoa (AETC)

EXPERIMENTAL

This group will receive 500mg cocoa capsules to be consumed daily and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% VO2peak) for 8 weeks

Dietary Supplement: Aerobic exercise + Theobroma cocoa (AETC)

Theobroma cocoa (TC)

EXPERIMENTAL

This group will receive 500mg cocoa capsules to be consumed daily for 8 weeks.

Dietary Supplement: Theobroma Cocoa (TC)

Interventions

Daily consumption of 500mg cocoa in capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.

Aerobic exercise + Theobroma cocoa (AETC)
Control Group (CG)DIETARY_SUPPLEMENT

Daily consumption of placebo capsules for 8 weeks

Control Group (CG)
Aerobic Exercise (AE)DIETARY_SUPPLEMENT

Daily consumption of placebo capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.

Aerobic Exercise (AE)
Theobroma Cocoa (TC)DIETARY_SUPPLEMENT

Daily consumption of 500mg cocoa in capsules for 8 weeks.

Theobroma cocoa (TC)

Eligibility Criteria

Age30 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Sedentary lifestyle (IPAQ- International Physical Activity Questionnaire);
  • Eutrophic or overweight (BMI \>18,5kg/m² and \<30kg/m²).

You may not qualify if:

  • Individuals with a feverish state and / or infectious disease;
  • Individuals with diabetes mellitus or coronary artery disease;
  • Individuals who have any recent cardiovascular events (last 3 months) or chronic renal failure; history of malignant diseases with life expectancy \<2 years;
  • Use of statins;
  • Smokers (those who have never smoked or smoked less than 100 cigarettes (5 bags of 20 cigarettes) in their lifetime and for at least 5 years);
  • Alcoholics (The WHO estabilish ad acceptable the consumption is up to 15 doses / week for men and 10 for women, with 1 dose equivalent to approximately 350 mL of beer, 150 mL of wine or 40 mL of a distilled drink, considering that each contains between 10 and 15 g of ethanol);

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia

Porto Alegre, Rio Grande do Sul, 90620001, Brazil

Location

MeSH Terms

Conditions

Sedentary BehaviorMotor Activity

Interventions

ExerciseControl GroupsASP protein, Theobroma cacao

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaEpidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Tainah Ortiz, M.Sc

    Instituto de Cardiologia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alexandre Lehnen, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Double
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 27, 2021

First Posted

February 1, 2021

Study Start

September 1, 2021

Primary Completion

September 1, 2022

Study Completion

December 10, 2022

Last Updated

August 20, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations